Tracey Lodie

Tracey Lodie has over 20 years of experience in the biotechnology and pharmaceutical industry. Tracey is currently serving as the Chief Scientific Officer at Quell Therapeutics since July 2021. Prior to this, Tracey held the role of CSO at Gamida Cell Ltd. from June 2019 until July 2021. Tracey also worked as the Senior Vice President of Translational Immunology at BlueRock Therapeutics from May 2017 to May 2019. Tracey served as the Vice President of Immunology at Syros Pharmaceuticals from July 2015 to May 2017. Tracey'searly career includes a notable role as the Senior Director of Immunology at Genzyme, a Sanofi company, from April 2001 to July 2015.

Tracey Lodie completed their Bachelor's Degree in Biology at Fairfield University from 1988 to 1992. Following their undergraduate studies, they pursued a Doctor of Philosophy (Ph.D.) in Immunology/Pathology at Boston University School of Medicine from 1994 to 1998. Later, from 1998 to 2001, they attended Harvard Medical School Beth Israel Hospital as a Postdoctoral Fellow in Hematology Oncology.